When two giants diverge: why Eli Lilly raced ahead while Novo Nordisk stumbled
It felt like a tilt-shift moment on the pharma leaderboard: one title-holder sprinting forward and another who’d dominated the same lane suddenly slowing to a stumble. On Wednesday, Eli Lilly’s share price surged after a bullish earnings call and an outsized 2026 revenue outlook, while Novo Nordisk’s stock slid on a gloomy forecast and mounting competitive pressures. The result is a widening gap between the two companies that had been racing in lockstep for the GLP‑1 weight-loss boom. (finance.yahoo.com)
Quick hits: what moved the market
- Eli Lilly raised expectations for 2026 revenue — targeting roughly $80–$83 billion — and beat Q4 estimates, giving investors confidence in continued growth. (finance.yahoo.com)
- Novo Nordisk surprised the market with guidance that implied a 5%–13% sales decline for 2026, signaling pressure from competition, pricing changes and regulatory headwinds. (finance.yahoo.com)
- Broader disruptions — cheaper compounded products, new entrants, and political scrutiny over drug pricing — accelerated the split between the two stocks. (investopedia.com)
How we got here: background and recent events
-
The context is the GLP‑1 revolution. Drugs like Lilly’s tirzepatide (Zepbound/Mounjaro family) and Novo’s semaglutide (Wegovy/Ozempic) redefined treatment for obesity and type 2 diabetes and produced rapid revenue growth for both companies in recent years. That boom set up intense competition and sky‑high expectations. (financialcontent.com)
-
Eli Lilly’s recent performance combined strong quarterly revenue (Q4 revenue above estimates) with a bold 2026 outlook — and investors interpreted that as evidence Lilly’s manufacturing, distribution and product mix are scaling well. The company’s oral GLP‑1 candidate and expanding market share in obesity care add to the narrative. (finance.yahoo.com)
-
Novo Nordisk’s outlook, by contrast, acknowledged a “painful transition” in a market facing price pressure and growing competition. Management signaled slower growth and even a potential sales decline next year — a message that markets punished quickly. Compounding this, cheaper and sometimes legally contested alternatives (and talk of regulatory intervention) have created noise and uncertainty around pricing and volume. (finance.yahoo.com)
Why the stocks diverged — the investor read
-
Forecasts matter: investors rewarded Lilly for projecting aggressive top‑line growth and beating quarterly expectations; they punished Novo for guiding to weaker sales. Forecast direction can change how a company is priced more than current-year results. (finance.yahoo.com)
-
Product positioning and pipeline: Lilly’s expanding GLP‑1 franchise (including oral programs) and its ability to ramp supply were read as durable advantages. Novo still leads in semaglutide brand recognition, but its comments suggest pricing and uptake will be tougher in 2026. (investing.com)
-
Pricing and politics: the U.S. spotlight on drug costs and moves by payers and regulators to curb prices change the math for high‑price specialty drugs. Lower list prices or tougher reimbursement reduce revenue even if patient demand remains large. That dynamic hit Novo’s outlook hard. (financialcontent.com)
-
Competitive noise: cheaper compounded formulations and new entrants (or an oral competitor) compress margins and create headline risk; investors reacted to both actual guidance and the possibility of faster price erosion. (investopedia.com)
What this means for investors and the market
-
Valuation repricing may be real. Stocks that once moved together now reflect differentiated risk profiles: Lilly seen as growth‑accelerating, Novo viewed as facing short‑term revenue headwinds. That opens trading and allocation decisions for investors who prefer growth vs stability. (marketbeat.com)
-
Short‑term volatility will likely persist. Headlines about pricing policies, regulatory rulings on compounded products, trial readouts for oral GLP‑1s, and quarterly guidance will swing sentiment quickly. (investopedia.com)
-
Longer-term winners will be decided by execution, not narrative. Lower prices could expand access and volume, which benefits whichever company controls manufacturing, distribution and payer relationships most effectively. Conversely, sharp margin erosion without offsetting volume gains would hurt profits. (financialcontent.com)
Risks and unanswered questions
- Will government and payer pressure force materially lower U.S. prices, and if so, can either company offset that with volume gains? (financialcontent.com)
- Which oral GLP‑1 or alternative delivery platforms will gain market share, and how will side‑effect profiles and adherence affect real‑world outcomes? (investing.com)
- Can either company defend pricing through patented delivery technologies, programmatic partnerships or by driving superior clinical outcomes? (investing.com)
My take
The split between Eli Lilly and Novo Nordisk isn’t a moral victory for one and a knockout for the other — it’s a re‑rating. Markets are reacting to forward guidance, pipeline signals and a changing regulatory environment. Lilly’s optimistic 2026 outlook and operational momentum bought it a premium; Novo’s candid warning about tougher times cost it investor confidence. Over the long run, scale, patient access and pricing mechanics will determine which company translates the GLP‑1 opportunity into sustainable profits. For now, expect headline‑driven moves and a lot of noise as the industry reshuffles.
Sources
Related update: We recently published an article that expands on this topic: read the latest post.
A surprising pivot from Insmed: what the BiRCh results mean for brensocatib and the company’s strategy
The biotech world loves dramatic arcs: a promising molecule rises, investors cheer, and then — sometimes — the plot takes an unexpected turn. On December 17, 2025, Insmed released topline results from the Phase 2b BiRCh study of brensocatib in chronic rhinosinusitis without nasal polyps (CRSsNP). The verdict was blunt: the study did not meet its primary or secondary efficacy endpoints. Insmed immediately discontinued the CRSsNP program, while also announcing the acquisition of a Phase 2-ready monoclonal antibody, INS1148, to bolster its respiratory and inflammatory pipeline.
Let’s unpack what happened, why it matters, and where Insmed might reasonably go from here.
Quick summary of the news
- Date of announcement: December 17, 2025.
- Study: Phase 2b BiRCh — brensocatib versus placebo in CRSsNP, 24 weeks, ~288 patients across 104 sites.
- Result: Neither the 10 mg nor 40 mg dose met the primary endpoint (change in sinus Total Symptom Score) or secondary endpoints.
- Safety: No new safety signals; tolerability consistent with prior studies, including in the higher 40 mg arm.
- Immediate corporate action: Insmed discontinued the CRSsNP development program for brensocatib.
- Simultaneous strategic move: Acquisition of INS1148 (OpSCF), a monoclonal antibody intended for interstitial lung disease and moderate-to-severe asthma; Insmed plans Phase 2 development.
Why the BiRCh failure matters
- Brensocatib had momentum. The drug showed promising results in non-cystic fibrosis bronchiectasis (NCFB) and had become a central part of Insmed’s growth story. Expectations built around expanding brensocatib into other inflammatory and respiratory indications.
- CRSsNP is biologically complex with no reliable animal models. Insmed described the BiRCh trial as a proof-of-concept aimed at testing whether brensocatib’s DPP1 inhibition could translate into symptom relief. The neutral result gives a clear — if disappointing — answer.
- Financial and R&D implications. Discontinuing a development program reduces near-term R&D spend on that indication, but it also cuts potential long-term upside if CRSsNP had proven a meaningful market. The market reaction (sharp stock drop reported in related coverage) reflects lost optionality and investor re-pricing of future revenue scenarios.
- Scientific signal. The lack of efficacy despite adequate dosing (including the company’s highest dose tested) raises mechanistic questions about neutrophil serine protease inhibition in CRSsNP specifically. It also tempers optimism for other indications where the drug’s mechanism is less directly validated.
What the data showed (topline numbers)
- Primary endpoint (28-day average of daily sTSS at Week 24):
- Placebo LS mean: -2.44
- Brensocatib 10 mg LS mean: -2.21
- Brensocatib 40 mg LS mean: -2.33
- Safety: Treatment-emergent adverse events were similar between arms; no new safety concerns, and serious adverse event rates were low and comparable.
Those numbers show minimal separation from placebo on symptom improvement — the clinical signal simply wasn’t there.
The strategic pivot: INS1148 acquisition
- What Insmed bought: INS1148 is a monoclonal antibody (formerly OpSCF) that targets a specific isoform of Stem Cell Factor (SCF248). The proposed advantage is to block the inflammatory cascade downstream of c-Kit signaling while sparing homeostatic/tissue-healing pathways.
- Initial focus: Insmed plans Phase 2 programs in interstitial lung disease and moderate-to-severe asthma. This aligns with the company’s pulmonary focus and offers a new, complementary modality (mAb vs small-molecule DPP1 inhibitor).
- Why this matters: Acquiring a clinical-stage asset diversifies Insmed’s pipeline at a time when brensocatib’s expansion into CRSsNP is off the table. It signals the company is doubling down on respiratory/inflammatory areas while mitigating the impact of the BiRCh result.
The investor dilemma
- Near-term pain: Market volatility is expected after a late-2025 negative readout on an eagerly watched indication. Analysts and short-term traders will re-evaluate revenue forecasts and valuation multiples.
- Longer-term perspective: Insmed still has commercial momentum from brensocatib in bronchiectasis (marketed as Brinsupri in some territories), other ongoing studies (e.g., hidradenitis suppurativa CEDAR study), and now INS1148 to potentially broaden indications. For investors with a multi-year horizon, the company’s runway and portfolio execution matter more than a single failed indication.
- Risk-reward recalibration: The failure reduces optionality and likely moderates peak-sales estimates for brensocatib overall. But the absence of new safety signals and the company’s ability to redeploy capital toward a novel mAb program may keep upside for those who believe in Insmed’s broader strategy.
What this means for brensocatib’s other programs
- Hidradenitis suppurativa (HS) and other non-pulmonary indications may be scrutinized more closely. A lack of efficacy in CRSsNP doesn’t doom those programs, but it raises caution and increases the value of positive, indication-specific data.
- For bronchiectasis, prior strong late-stage results remain intact. Regulatory and commercial timelines for that indication are independent of the CRSsNP result, but market expectations may be tempered.
Takeaways for clinicians, patients, and industry watchers
- Clinicians and patients with CRSsNP: The BiRCh data suggest brensocatib will not become an option for CRSsNP. Patients should continue following evidence-based care and consult their physicians for approved therapies and management strategies.
- Industry watchers: This is a reminder that translating mechanism-based therapies into symptom relief in human disease is hard, especially in diseases lacking translational animal models. Creative acquisitions (like INS1148) are a common industry response to maintain pipeline momentum.
My take
Insmed’s BiRCh outcome is a textbook example of how clinical development reorders expectations. The result is disappointing, but not catastrophic: the company still has a commercially relevant product in bronchiectasis and a pipeline it can re-shape. Acquiring INS1148 is a pragmatic move — it signals an appetite to diversify modality risk and lean into respiratory immunology with a different mechanism.
Failures like this sting publicly because they are visible and immediate. But they can also sharpen corporate focus. If Insmed executes well on ongoing brensocatib programs and advances INS1148 thoughtfully into Phase 2, the company can emerge with a clearer, perhaps stronger strategic identity — albeit one that looks different than the path investors may have anticipated at the start of 2025.
Further reading
- Insmed press release: “Insmed Provides Clinical and Business Update” (December 17, 2025) — for the full topline text and company commentary.
- Reuters and other industry coverage — for market reaction and context around brensocatib’s prior successes in bronchiectasis.
Sources
Related update: We recently published an article that expands on this topic: read the latest post.
When a Rival’s Win Becomes Your Windfall
Bristol Myers Squibb (BMY) got a bump on Monday — not because of its own press release, but because Bayer released what analysts called a “surprisingly positive” update on its experimental blood thinner, asundexian. The result: investors breathed new life into the broader class of Factor XIa inhibitors and pushed Bristol Myers shares higher. It’s one of those market moments that shows how biotech is often a group sport — your competitor’s breakthrough can validate your pipeline overnight.
Why a Bayer trial moved Bristol Myers
- Bayer’s Phase III OCEANIC‑STROKE trial reported that asundexian (50 mg daily), given with standard antiplatelet therapy, significantly reduced recurrent ischemic stroke risk in patients after a non‑cardioembolic ischemic stroke or high‑risk transient ischemic attack — and crucially, without increasing major bleeding. (bayer.com)
- Factor XIa inhibitors (the drug class) aim to uncouple thrombosis from normal hemostasis — meaning they could prevent clotting events like stroke while lowering bleeding risk compared with existing anticoagulants. That mechanism is precisely what drug developers such as Bristol Myers (milvexian) and others are trying to prove. (bayer.com)
- Investors treat successful late‑stage results for one program as partial proof‑of‑concept for the whole class. Bayer’s win raised the perceived odds that similar molecules — including Bristol Myers’ milvexian — can succeed in at least some indications, which translated into a multi‑percent pop in BMY stock. (investors.com)
A quick look at the players and timeline
- Bayer: announced positive topline results from OCEANIC‑STROKE on November 23, 2025, and said detailed results will be presented at an upcoming scientific congress. The company plans to engage regulators about potential marketing applications. (bayer.com)
- Bristol Myers Squibb: developing milvexian, another oral Factor XIa inhibitor. Milvexian had an earlier setback when an acute coronary syndrome (ACS) trial was halted for likely futility, but analysts now see greater odds for success in secondary stroke prevention after Bayer’s news. Bristol Myers expects key readouts for atrial fibrillation and stroke indications in 2026 (stroke) and late 2026 (AF study topline timing noted by analysts). (investors.com)
- Regeneron and other firms: also saw small moves after Bayer’s announcement, reflecting industry‑wide implications for the FXIa inhibitor class. (investors.com)
Why investors care beyond a single trial result
- The unmet-need math is compelling: recurrent stroke risk remains high, and current oral anticoagulants (like Factor Xa inhibitors) come with bleeding tradeoffs that limit use in some patients. A therapy that meaningfully lowers ischemic stroke risk without increasing major bleeding could shift practice and command large market share. (bayer.com)
- Drug development in cardiovascular and stroke indications often translates into multibillion‑dollar peak sales if regulators and clinicians accept the benefit/risk profile — which is why analysts quickly remapped revenue forecasts after Bayer’s topline. (investors.com)
- But “class validation” isn’t a guarantee. Molecules differ in pharmacology, trial designs matter, and regulatory hurdles remain. A positive headline helps, but each candidate must prove itself on its own data.
What to watch next
- Full data release: details on event rates, absolute risk reduction, subgroup analyses, and bleeding definitions (ISTH major bleeding vs. other metrics) will determine how convincing the result really is. Bayer said full results will be presented at a scientific meeting. (bayer.com)
- Bristol Myers’ milvexian readouts: timing and endpoints for milvexian’s stroke and atrial fibrillation trials — and whether milvexian reproduces asundexian’s safety/efficacy balance. Analysts have already increased probability estimates for some milvexian indications; the market will watch for Bristol’s own numbers. (investors.com)
- Regulatory feedback: Bayer plans to engage health authorities about applications; regulators’ responses (and any requests for additional data) will shape the approval timeline and commercial prospects. (reuters.com)
Market and scientific nuance
- Proof‑of‑concept at large scale: OCEANIC‑STROKE reportedly enrolled over 12,000 patients — a sizable dataset that, if robust, gives the result weight beyond small, early trials. Large phase III success can be a genuine inflection point. (bayer.com)
- Not all indications are equal: Bayer’s win was in secondary stroke prevention; earlier failures (e.g., atrial fibrillation) remind us that efficacy can vary by disease context. Analysts noted Bayer’s prior AF setback and cautioned extrapolating to every indication. (reuters.com)
- Competitive landscape: multiple companies are racing to develop FXIa inhibitors. A first approval for the class would change competitive dynamics rapidly, but differentiation (oral dosing, safety, efficacy in key subgroups) will matter for long‑term market share.
A few bite‑sized takeaways
- Bayer’s OCEANIC‑STROKE topline appears to validate the therapeutic potential of FXIa inhibition for secondary stroke prevention. (bayer.com)
- That validation lifted investor sentiment for peers, including Bristol Myers, which benefits from a stronger belief in milvexian’s prospects despite prior setbacks. (investors.com)
- Full data, regulatory reviews, and individual trial differences still determine winners — a class win is helpful, but not decisive.
My take
This is what makes biotech markets both thrilling and maddening: a single credible late‑stage readout can switch narratives overnight. Bayer’s result is an important proof‑point for Factor XIa inhibition and opens the door for rivals — but each program still needs to clear its own clinical and regulatory hurdles. For long‑term investors or clinicians, the sensible posture is curiosity plus scrutiny: welcome the class validation, then ask for the full data and watch how each molecule performs in its own trials.
Sources
Related update: We recently published an article that expands on this topic: read the latest post.
Related update: We recently published an article that expands on this topic: read the latest post.
Tom Brady cloned his dead dog — and it reads like a billionaire’s PR move
You know when a celebrity announcement lands and you can’t tell if it’s sincere grief, a flex, or a marketing stunt? Tom Brady’s recent revelation that his current dog Junie is a genetic clone of his late dog Lua checks all three boxes — and then some. The news landed alongside a corporate update from Colossal Biosciences, the biotech firm Brady has invested in, and set off a predictable storm of fascination, skepticism, and ethical hand-wringing. (defector.com)
Why this feels less like a private family moment and more like a brand activation
- Tom Brady’s announcement coincided with Colossal Biosciences’ acquisition of Viagen Pets and Equine — a company that does commercial pet cloning — making the reveal read like a perfectly timed PR play. (statesman.com)
- Brady is publicly invested in Colossal, so his glowing comments about cloning double as social proof for a company aiming to normalize high-profile animal cloning and sell an ambitious public story about “de‑extinction” and conservation. (people.com)
- The optics are weirdly modern-feudal: a billionaire uses cutting-edge biotech to buy back what death took, then makes the purchase part of the company narrative. People notice when private grief overlaps with corporate messaging. (defector.com)
A quick primer: what actually happened (the short version)
- Lua, a pit-bull mix that belonged to Brady’s family, died in December 2023. A blood draw taken before her death was used to preserve her DNA. (people.com)
- Colossal Biosciences — which Brady has invested in — says it used non-invasive cloning technology to create Junie, an animal with the same genetic makeup as Lua. The announcement coincided with Colossal’s purchase of Viagen, a company known for cloning celebrity pets. (statesman.com)
- Commercial pet cloning typically carries high price tags (public reports have cited something like $50,000 for cats or dogs through Viagen), and it’s not cheap or frictionless. (statesman.com)
Science, limits, and the “it’s not the same dog” argument
Genetic identity is not identity-of-experience. Cloning gives you the same genome, not the same life history. Personality, temperament, and quirks result from interactions with environment, maternal conditions in utero, early socialization, and random developmental events — all things a clone will experience differently. Scientists and animal cognition experts have made this clear repeatedly: clones resemble but do not replicate lived personality. (defector.com)
There are also practical realities of pet cloning:
- Success rates for dog cloning have improved since the early, painstaking work (Snuppy in 2005), but cloning remains technically demanding and often involves low yield and surrogate animals. (defector.com)
- The procedure carries ethical questions about the use of surrogates and the fate of embryos and failed attempts, plus animal welfare concerns around the whole process. (defector.com)
The larger story: investors, de‑extinction, and PR theater
Colossal markets itself as a company that can revive extinct species and help conserve endangered ones. Pet cloning is an immediately marketable, emotionally resonant offshoot that also generates headlines and revenue. Having a celebrity investor publicly clone a beloved pet offers three benefits:
- It humanizes and legitimizes a controversial technology.
- It ties a sentimental narrative to a corporate milestone (the Viagen deal).
- It creates cultural conversation — which is cheap PR when coordinated around celebrity announcements. (people.com)
That coordination is why many readers called Brady’s announcement a “brand activation”: the timing and the corporate connection make it hard to read as purely private grief. For public-facing biotech, headlines and cultural cachet can be as valuable as scientific progress, and celebrities are unusually effective at generating both.
Social reaction and cultural vibes
Responses have been all over the map:
- Some people find cloning comforting — a chance to spend more time with an animal that was deeply loved. (people.com)
- Others see it as tone-deaf (given high numbers of shelter animals), ethically fraught, or simply emotionally misguided — a replacement, not a resurrection. Online reactions skewed skeptical and at times outraged. (defector.com)
A few practical questions this raises
- What does a clone cost an average owner versus what Brady likely paid (or leveraged through investment ties)? Public numbers for Viagen services have circulated, but celebrity deals can blur price transparency. (statesman.com)
- How does commercial pet cloning affect shelter adoption rates and resources? If cloning normalizes “buying back” pets, it could have ripple effects in how people view and source companion animals.
- Where do we draw ethical lines between conservation goals and consumerized cloning for grief or vanity? Colossal’s stated conservation ambitions invite scrutiny when the company also markets celebrity pet cloning. (defector.com)
Things to remember
- A clone is a genetic twin, not a memory machine. Expect resemblance, not reincarnation. (defector.com)
- Celebrity announcements that align closely with a company’s corporate milestones should be read with a PR-skeptical eye. Timing matters. (defector.com)
My take
Grief is complicated and people find comfort in different ways. If cloning a beloved pet genuinely helped Brady’s family, that human element deserves empathy. But when the personal becomes entangled with investments and corporate narrative, we should scrutinize the optics and the industry incentives.
This isn’t just a weird rich-guy anecdote — it’s a cultural touchpoint for how emerging biotech will be marketed, normalized, and regulated. Celebrity validation can accelerate adoption, for better or worse, so the conversation we have now about ethics, transparency, and animal welfare matters.
Where to read more
- Defector’s take on the timing, optics, and irony of Brady’s announcement. (defector.com)
- People’s reporting on Brady’s statement and Colossal’s role in cloning Junie from Lua’s preserved blood sample. (people.com)
- Local coverage on Colossal’s involvement and Viagen’s cloning services and pricing. (statesman.com)
Sources
Related update: We recently published an article that expands on this topic: read the latest post.
Related update: We recently published an article that expands on this topic: read the latest post.
Related update: We recently published an article that expands on this topic: read the latest post.
Related update: We recently published an article that expands on this topic: read the latest post.
